Methamphetamine - Revision history

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:09Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 15:		Line 15:
	\| pregnancy = Category C (per Desoxyn label)		\| pregnancy = Category C (per Desoxyn label)
	\| legal = Schedule II		\| legal = Schedule II
	\| mechanism = Monoamine releasing agent — TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport		\| mechanism = Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport
	\| intro = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.		\| intro = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.
	\| indications = <problem slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/>		\| indications = <problem slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/>
Line 50:		Line 50:
	\| pk_elimination = Urinary elimination is pH-dependent.		\| pk_elimination = Urinary elimination is pH-dependent.
	\| pharmacodynamics = Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.		\| pharmacodynamics = Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.
	\| interactions = * '''MAOIs''' — contraindicated (per label)		\| interactions = * '''MAOIs''', contraindicated (per label)
	* '''Acidifying agents''' — increase urinary clearance		* '''Acidifying agents''', increase urinary clearance
	* '''Alkalinizing agents''' — decrease urinary clearance		* '''Alkalinizing agents''', decrease urinary clearance
	<pharmaInteractions/>		<pharmaInteractions/>
	\| pregnancy_details = Category C per Desoxyn label.		\| pregnancy_details = Category C per Desoxyn label.

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:50:49Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:50, 17 May 2026
Line 63:		Line 63:


	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]
	[[Category:Amphetamines]]		[[Category:Amphetamines]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Phenethylamines]]		[[Category:Phenethylamines]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:45:04Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:45, 17 May 2026
Line 63:		Line 63:


	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]
	[[Category:Amphetamines]]		[[Category:Amphetamines]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Phenethylamines]]		[[Category:Phenethylamines]]

MDElliottMD: Migrate tags to (Phase 2 of indications-to-problems rebuild)

2026-05-17T00:11:51Z

Migrate <indication> tags to <problem> (Phase 2 of indications-to-problems rebuild)

← Older revision		Revision as of 00:11, 17 May 2026
Line 17:		Line 17:
	\| mechanism = Monoamine releasing agent — TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport		\| mechanism = Monoamine releasing agent — TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport
	\| intro = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.		\| intro = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.
	\| indications = <~~indication~~ slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/>		\| indications = <problem slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/>
	<~~indication~~ slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/>		<problem slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/>
	\| dosing = \| effects =		\| dosing = \| effects =
	* <effect ref="attention" author="MDElliottMD"/>		* <effect ref="attention" author="MDElliottMD"/>

MDElliottMD: Comprehensive categorization: +Phenethylamines

2026-05-15T18:42:02Z

Comprehensive categorization: +Phenethylamines

← Older revision		Revision as of 18:42, 15 May 2026
Line 66:		Line 66:
	[[Category:Amphetamines]]		[[Category:Amphetamines]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
			[[Category:Phenethylamines]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:54Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 62:		Line 62:
	}}		}}


			[[Category:Stimulants & Wake-Promoting Agents]]
			[[Category:Amphetamines]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:58Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 53:		Line 53:
	* '''Acidifying agents''' — increase urinary clearance		* '''Acidifying agents''' — increase urinary clearance
	* '''Alkalinizing agents''' — decrease urinary clearance		* '''Alkalinizing agents''' — decrease urinary clearance
			<pharmaInteractions/>
	\| pregnancy_details = Category C per Desoxyn label.		\| pregnancy_details = Category C per Desoxyn label.
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:41Z

Pharmacopedia: remove contraindications parameter

@@ Line 50: / Line 50: @@
 | pk_elimination    = Urinary elimination is pH-dependent.
 | pharmacodynamics  = Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.
 | interactions      = * '''MAOIs''' — contraindicated (per label)
 * '''Acidifying agents''' — increase urinary clearance

MDElliottMD at 06:12, 13 May 2026

2026-05-13T06:12:26Z

← Older revision		Revision as of 06:12, 13 May 2026
Line 2:		Line 2:
	\| generic = Methamphetamine		\| generic = Methamphetamine
	\| brand = Desoxyn		\| brand = Desoxyn
	\| structure =		\| structure = Methamphetamine.svg
	\| classes = Psychostimulant, Amphetamine		\| classes = Psychostimulant, Amphetamine
	\| uses = <vote slug="inattention-meth">Inattention</vote>, <vote slug="hyperactivity-meth">Hyperactivity</vote>, <vote slug="obesity-meth">Obesity</vote>		\| uses = <vote slug="inattention-meth">Inattention</vote>, <vote slug="hyperactivity-meth">Hyperactivity</vote>, <vote slug="obesity-meth">Obesity</vote>

MDElliottMD: Removed titration "adhd-desoxyn"

2026-05-13T06:09:45Z

Removed titration "adhd-desoxyn"

← Older revision		Revision as of 06:09, 13 May 2026
Line 19:		Line 19:
	\| indications = <indication slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/>		\| indications = <indication slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/>
	<indication slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/>		<indication slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/>
	\| dosing = ~~<titration slug="adhd-desoxyn" title="ADHD — per Desoxyn label" author="MDElliottMD">~~		\| dosing = \| effects =
	~~Per the Desoxyn prescribing information, see the official label for current dosing guidance.~~
	~~</titration>~~
	\| effects =
	* <effect ref="attention" author="MDElliottMD"/>		* <effect ref="attention" author="MDElliottMD"/>
	* <effect ref="wakefulness" author="MDElliottMD"/>		* <effect ref="wakefulness" author="MDElliottMD"/>